
|Videos|November 12, 2021
Bausch + Lomb: Update on FDA approval of XIPERE for macular edema associated with uveitis
Author(s)David Hutton, Alex Delaney-Gesing
Bausch + Lomb's Yolande Barnard, shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.
Advertisement
Ophthalmology Times'® David Hutton speaks with Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, on the company's latest
XIPERE is the first—and currently only— FDA-approved therapy utilizing suprachoridal administration.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
2
First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis
3
NCX 470 gains positive regulatory feedback in China ahead of US NDA submission
4
Real-World Experience With Aflibercept 8 mg in Retinal Vascular Diseases
5























